ATE399164T1 - Antagonisten des opioidrezeptors - Google Patents

Antagonisten des opioidrezeptors

Info

Publication number
ATE399164T1
ATE399164T1 AT05724568T AT05724568T ATE399164T1 AT E399164 T1 ATE399164 T1 AT E399164T1 AT 05724568 T AT05724568 T AT 05724568T AT 05724568 T AT05724568 T AT 05724568T AT E399164 T1 ATE399164 T1 AT E399164T1
Authority
AT
Austria
Prior art keywords
antagonists
opioid receptor
racemate
diastereomer
amelioration
Prior art date
Application number
AT05724568T
Other languages
English (en)
Inventor
Howard BROUGHTON
Buezo Nuria Lilly Diaz
Charles Mitch
Concepcion Li Pedregal-Tercero
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE399164T1 publication Critical patent/ATE399164T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91Dibenzofurans; Hydrogenated dibenzofurans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14[b,f]-condensed
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05724568T 2004-03-12 2005-03-08 Antagonisten des opioidrezeptors ATE399164T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04380057 2004-03-12
US55318704P 2004-03-15 2004-03-15

Publications (1)

Publication Number Publication Date
ATE399164T1 true ATE399164T1 (de) 2008-07-15

Family

ID=46045513

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05724568T ATE399164T1 (de) 2004-03-12 2005-03-08 Antagonisten des opioidrezeptors

Country Status (7)

Country Link
US (1) US7288543B2 (de)
EP (1) EP1730140B1 (de)
JP (1) JP2007528898A (de)
AT (1) ATE399164T1 (de)
CA (1) CA2558652A1 (de)
ES (1) ES2308471T3 (de)
WO (1) WO2005090337A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2208727T1 (sl) * 2002-09-19 2012-11-30 Lilly Co Eli Diaril etri kot antagonisti opioidnega receptorja
CA2558030A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
EP2152671A1 (de) 2007-05-22 2010-02-17 Prosidion Limited Bicyclische aryl- und heteroarylverbindungen zur behandlung von stoffwechselerkrankungen
WO2009030962A1 (en) 2007-09-07 2009-03-12 Prosidion Limited Bicyclic aryl and heteroaryl receptor modulators
JP5345637B2 (ja) * 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
BR112012006069A8 (pt) * 2009-09-18 2017-10-10 Adolor Corp Método para tratar ou prevenir constipação induzida e disfunção intestinal induzida por opióide em um humano, e, uso de uma quantidade terapeuticamente efetiva de composto
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
IL315415A (en) 2022-03-07 2024-11-01 Janssen Pharmaceuticals Inc The compositions containing eticarpant
KR20240156409A (ko) 2022-03-07 2024-10-29 얀센 파마슈티칼즈, 인코포레이티드 주요 우울 장애 치료에 사용을 위한 아티카프란트의 다형 형태

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678779A (en) * 1985-01-31 1987-07-07 Meyers Vera K Weight control method
DE4215213A1 (de) * 1992-05-09 1993-11-11 Merck Patent Gmbh Arylacetamide
SI2208727T1 (sl) 2002-09-19 2012-11-30 Lilly Co Eli Diaril etri kot antagonisti opioidnega receptorja
CN1753884A (zh) 2003-03-07 2006-03-29 伊莱利利公司 阿片类受体拮抗剂
EP1613597B1 (de) 2003-03-07 2007-11-07 Eli Lilly and Company 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten
BRPI0417156A (pt) 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
ES2390459T3 (es) 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides

Also Published As

Publication number Publication date
EP1730140B1 (de) 2008-06-25
JP2007528898A (ja) 2007-10-18
ES2308471T3 (es) 2008-12-01
WO2005090337A1 (en) 2005-09-29
US7288543B2 (en) 2007-10-30
EP1730140A1 (de) 2006-12-13
CA2558652A1 (en) 2005-09-29
US20070179129A1 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
ATE545413T1 (de) Antagonisten des opioidrezeptors
NO20051871L (no) Opioidreseptorantagonister
TW200716574A (en) The preparation and use of compounds as aspartyl protease inhibitors
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
TW200716520A (en) 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
ECSP066640A (es) Inhibidores heterocíclicos de aspartil proteasa
ATE475640T1 (de) Antagonisten des opioidrezeptors
GB0225475D0 (en) Therapeutic agents
MY149183A (en) Heterocyclic aspartyl protease inhibitors
ATE406360T1 (de) Antagonisten der opioidrezeptoren
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
TW200607807A (en) Macrocyclic beta-secretase inhibitors
ATE446962T1 (de) Thiazolopyridinon-derivate als mch- rezeptorantagonisten
WO2007146758A3 (en) Novel mch receptor antagonists
ATE384058T1 (de) Thiazolderivate
HRP20130614T1 (en) Novel pyrazole-substituted arylamides
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
PT1828177E (pt) Novos antagonistas dos receptores da mch
ATE399164T1 (de) Antagonisten des opioidrezeptors
SE0401655D0 (sv) New compounds
WO2006134486A3 (en) Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists
TW200621223A (en) Acyclic 1,3-diamines and uses therefor
TW200612912A (en) Benzyloxy derivatives as maob inhibitors
EA015500B9 (ru) Новые антагонисты мсн рецепторов

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties